Viyash Scientific Limited (formerly Sequent Scientific) announced robust financial results for Q3 FY26. Revenues increased by 10.9% to ₹8,584 Million, and EBITDA surged by 64.4% to ₹1,854 Million. For the nine-month period, revenues reached ₹25,004 Million, up by 11.9%, with EBITDA at ₹5,024 Million, marking a 58% increase. The company also reported strong PAT growth and a reduced Net Debt to EBITDA ratio.
Financial Performance Highlights
Viyash Scientific Limited reported strong financial performance for the quarter ended December 31, 2025 (Q3 FY26), marking the first combined results post-merger. Here’s a summary:
- Revenue: Increased by 10.9% to ₹8,584 Million.
- EBITDA: Rose significantly by 64.4%, reaching ₹1,854 Million.
- EBITDA Margin: Stood at 21.6%.
- PAT: Increased by 15.5%.
Nine-Month Performance (FY26)
The company’s performance over the nine-month period also demonstrated significant growth:
- Revenue: Grew by 11.9% to ₹25,004 Million.
- EBITDA: Saw an increase of 58%, amounting to ₹5,024 Million.
- EBITDA Margin: Stood at 20.1%.
- PAT: Increased by 230%.
Key Developments
Viyash Scientific has successfully reduced its Net Debt / EBITDA ratio to 0.38x.
Management Commentary
Dr Hari Babu Bodepudi, Managing Director and Group CEO, commented on the results, stating that the company marks a significant milestone by announcing the merged entity’s results for the first time. He emphasized the strong growth in revenue, margins, and profitability, driven by new product introductions, cost improvement, and synergies across business units. He also highlighted the company’s strong balance sheet and market position, positioning it well for future market opportunities.
Earnings Call Information
The company will host an earnings call on February 06, 2025, at 17:30 IST to discuss the company’s performance and address questions from participants. Dial-in numbers are +91 22 6280 1263 or +91 22 7115 8213.
Source: BSE
